KR20150142691A - 테트란드린 패밀리 제약 제제 및 방법 - Google Patents
테트란드린 패밀리 제약 제제 및 방법 Download PDFInfo
- Publication number
- KR20150142691A KR20150142691A KR1020157029740A KR20157029740A KR20150142691A KR 20150142691 A KR20150142691 A KR 20150142691A KR 1020157029740 A KR1020157029740 A KR 1020157029740A KR 20157029740 A KR20157029740 A KR 20157029740A KR 20150142691 A KR20150142691 A KR 20150142691A
- Authority
- KR
- South Korea
- Prior art keywords
- family member
- pharmaceutical
- family
- formula
- disodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 title claims description 11
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 title claims description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 10
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 13
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 abstract description 3
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792849P | 2013-03-15 | 2013-03-15 | |
| US61/792,849 | 2013-03-15 | ||
| PCT/US2014/021195 WO2014149848A1 (en) | 2013-03-15 | 2014-03-06 | Tetrandrine family pharmaceutical formulations and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150142691A true KR20150142691A (ko) | 2015-12-22 |
Family
ID=51529969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157029740A Ceased KR20150142691A (ko) | 2013-03-15 | 2014-03-06 | 테트란드린 패밀리 제약 제제 및 방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9517234B2 (enExample) |
| EP (1) | EP2968310A4 (enExample) |
| JP (1) | JP2016512818A (enExample) |
| KR (1) | KR20150142691A (enExample) |
| CN (1) | CN105358149A (enExample) |
| MX (1) | MX2015013155A (enExample) |
| WO (1) | WO2014149848A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576077B2 (en) | 2015-03-23 | 2020-03-03 | Southwest Research Institute | Pharmaceutical salt forms of Cepharanthine and Tetrandrine |
| CN107260694A (zh) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂 |
| CN112402419B (zh) * | 2019-08-23 | 2023-12-08 | 华东理工大学 | 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用 |
| CN111675717B (zh) * | 2020-06-21 | 2023-04-07 | 兰州理工大学 | 粉防己单体化合物及其提取方法和用途 |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN114159438B (zh) * | 2021-11-30 | 2023-07-18 | 首都医科大学附属北京安定医院 | 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4569852A (en) * | 1983-08-23 | 1986-02-11 | Warner-Lambert Company | Maintenance of flavor intensity in pressed tablets |
| JPH0678232B2 (ja) * | 1986-03-07 | 1994-10-05 | 株式会社ツムラ | アンジオテンシンｉ転換酵素阻害剤 |
| JPH0678231B2 (ja) * | 1986-03-08 | 1994-10-05 | 株式会社ツムラ | 血液粘度低下剤 |
| JPH0733388B2 (ja) * | 1987-01-22 | 1995-04-12 | 株式会社ツムラ | 新規アルカロイド |
| JPH02243627A (ja) * | 1989-03-16 | 1990-09-27 | Tsumura & Co | 狭心症治療薬 |
| US5332747A (en) | 1989-09-28 | 1994-07-26 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells |
| US6911454B1 (en) | 1989-09-28 | 2005-06-28 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant disease |
| US5025020A (en) | 1989-09-28 | 1991-06-18 | Cancer Biologics Of America, Inc. | Use of tetrandrine and its derivatives to treat malaria |
| JPH0499723A (ja) * | 1990-08-17 | 1992-03-31 | Kaken Shiyouyaku Kk | ウイルス・ゲノム不活化剤 |
| US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5627195A (en) * | 1995-04-11 | 1997-05-06 | Massachusetts Eye And Ear Infirmary | Treatment for ocular inflammation |
| US6218541B1 (en) | 1999-06-28 | 2001-04-17 | Cba, International, Inc. | Method for extracting bisbenzylisoquinolines |
| IL144760A0 (en) * | 1999-12-08 | 2002-06-30 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| US20050245559A1 (en) * | 2004-01-23 | 2005-11-03 | Koul Hari K | Treatment and prevention of prostate cancer |
| MX2009000923A (es) * | 2006-08-04 | 2009-03-09 | Agi Therapeutics Res Ltd | Metodos para tratar cuando menos una condicion que tiene receptor de mt1, receptor de 5ht2b, y actividad de canal de calcio tipo l. |
| AU2009215514B9 (en) * | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| EP2241561A1 (en) | 2009-04-16 | 2010-10-20 | Neuron Biopharma, S.A. | Neuroprotective, hypocholesterolemic and antiepileptic compound |
| WO2011056965A1 (en) | 2009-11-05 | 2011-05-12 | Cba International, Inc. | Method for extracting and purifying bisbenzylisoquinolines |
| EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| CN104955330A (zh) * | 2012-09-13 | 2015-09-30 | Cba制药有限公司 | 粉防己碱药物制剂及方法 |
| CN102898433B (zh) * | 2012-09-26 | 2015-04-15 | 中国医药研究开发中心有限公司 | 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途 |
| JP2015531355A (ja) * | 2012-09-28 | 2015-11-02 | ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 腫瘍治療のための薬剤組成物及びその適用 |
-
2014
- 2014-03-06 EP EP14767576.3A patent/EP2968310A4/en not_active Withdrawn
- 2014-03-06 KR KR1020157029740A patent/KR20150142691A/ko not_active Ceased
- 2014-03-06 US US14/199,235 patent/US9517234B2/en active Active
- 2014-03-06 CN CN201480028296.6A patent/CN105358149A/zh active Pending
- 2014-03-06 MX MX2015013155A patent/MX2015013155A/es unknown
- 2014-03-06 WO PCT/US2014/021195 patent/WO2014149848A1/en not_active Ceased
- 2014-03-06 JP JP2016500735A patent/JP2016512818A/ja active Pending
-
2016
- 2016-11-08 US US15/346,022 patent/US10023584B2/en active Active
- 2016-11-08 US US15/346,054 patent/US20170050976A1/en not_active Abandoned
-
2018
- 2018-06-20 US US16/012,872 patent/US10815243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180298022A1 (en) | 2018-10-18 |
| US10815243B2 (en) | 2020-10-27 |
| WO2014149848A1 (en) | 2014-09-25 |
| MX2015013155A (es) | 2016-04-04 |
| US20140275137A1 (en) | 2014-09-18 |
| US20170050976A1 (en) | 2017-02-23 |
| CN105358149A (zh) | 2016-02-24 |
| US10023584B2 (en) | 2018-07-17 |
| EP2968310A1 (en) | 2016-01-20 |
| US9517234B2 (en) | 2016-12-13 |
| US20170050975A1 (en) | 2017-02-23 |
| EP2968310A4 (en) | 2017-01-11 |
| JP2016512818A (ja) | 2016-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114340608B (zh) | 一种药物组合物及其应用 | |
| US10815243B2 (en) | Tetrandrine family pharmaceutical formulations and method | |
| BRPI0912112B1 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
| US20140275139A1 (en) | Mdr method and products for treating hiv/aids | |
| HRP20170564T1 (hr) | Derivati aminociklobutana, metoda njihove priprave i njihova upotreba za lijekove | |
| CN111233878B (zh) | 一种加兰他敏双羟萘酸盐及其制备方法 | |
| EP4316493A1 (en) | Novel use of cyclic ketone compound | |
| CN104955330A (zh) | 粉防己碱药物制剂及方法 | |
| WO2007143895A1 (fr) | Solution supersaturée de chlorhydrate de gemcitabine et son procédé de préparation | |
| JP2025011312A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| JP2025015727A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 | |
| RU2745985C1 (ru) | Антикоронавирусный терапевтический агент - замещенный 7-гидрокси-3,4,12,12а-тетрагидро-1H-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион для профилактики и лечения COVID-19 | |
| CN111233877B (zh) | 一种加兰他敏帕莫酸盐及其制备方法 | |
| CN102302495A (zh) | 一种供注射用盐酸托烷司琼药物组合物 | |
| US20140073591A1 (en) | Mdr method and products for treating mrsa | |
| KR20150143504A (ko) | 약물 및 영양 보조식품의 생체이용률을 증진시키기 위한 방법 및 생성물 | |
| US6784315B2 (en) | Stilbene derivative crystal and method for producing the same | |
| US20140275138A1 (en) | Method and products for treating diabetes | |
| RU2851166C1 (ru) | Фармацевтическая композиция и ее применение | |
| US20240382507A1 (en) | Pharmaceutical compositions comprising 2,3,4,5- tetrahydrobenzothiepin- 1,1-dioxide derivatives and the use thereof | |
| JP2016514143A (ja) | 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物 | |
| HK40063844A (en) | Pharmaceutical composition and use thereof | |
| RU2574397C1 (ru) | Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в | |
| HK40085950A (en) | Compound for use in the treatment of dry mouth | |
| CN103933034A (zh) | 一种含有木犀草素的药物组合物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151015 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190228 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200601 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210401 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200601 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |